AzTrials
AzTrials

Alcohol Dependence, in RemissionPhase 2NCT04990765

Virtual Reality-Assisted Cognitive Behavioral Therapy for Alcohol Dependence (CRAVR-Pilot)

A Phase 2 study testing Virtual Reality Cognitive Behavioral Therapy (CRAVR) and CBT in people with Alcohol Dependence, in Remission and Addiction, Alcohol, run by Psychiatric Centre Rigshospitalet at 1 site in Denmark.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The pilot study is a single-blinded, randomized, controlled, 2 months clinical trial. The objective is to investigate the feasibility, effects and side-effects of virtual reality-assisted cognitive behavioral therapy (VR-CBT) vs. Read more about this study

Who is it for?
Ages 18 to 70 years
What is being tested?
Virtual Reality Cognitive Behavioral Therapy (CRAVR) and CBT
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteDenmark
Study dates
11 May 2021to 20 Oct 2021
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Informed oral and written consent
  • Meets criteria for alcohol dependence syndrome according to International Classification of Diseases (ICD) 10, WHO \& Diagnostic and Statistical Manual of Mental Disorder (DSM-5)
  • Age 18 - 70 years old (both included)
  • Minimum 5 'heavy drinking days' in the last month, which is defined as an alcohol intake above 60/48 grams or 5/4 items per. day for resp. men and women over the past 30 days

Who cannot join

  • Other active substance use defined by DUDIT score> 6 (for men)> 2 (for women) and meet the criteria for other drug dependence according to ICD-10 (excluding nicotine)
  • Does not speak or understand Danish
  • Mental retardation or known severe psychiatric illness or other condition where it is assessed that will interfere with participation eg severely impaired vision or hearing.
  • Medical alcohol treatment (disulfiram, acamprosate, naltrexone or nalmefen) within the latest 4 weeks and during the treatment period

Trial locations and contacts

1 site in 1 country.

Anders Fink-Jensen, MD, DMSc contact

+45 22755843

anders.fink-jensen@regionh.dk

Daniel Thaysen Petersen, MD contact

+4528777938

daniel.thaysen.petersen@regionh.dk

Denmark1 site, 1 recruiting
  • Novavi ambulatorierne

    Copenhagen, Frederiksberg, 2000

    Signe W. Düring, MD, PhD, SDUR@novavi.dk

    Recruiting

Other trials in Denmark

About this study

Official title: Virtual Reality-Assisted Cognitive Behavioral Therapy for Alcohol Dependence: A Pilot Study (CRAVR-Pilot)

The pilot study is a single-blinded, randomized, controlled, 2 months clinical trial. The objective is to investigate the feasibility, effects and side-effects of virtual reality-assisted cognitive behavioral therapy (VR-CBT) vs. cognitive behavioral therapy (CBT) on alcohol intake in patients with a diagnosis of alcohol dependence.

Read the detailed description

Pilot study rational:

Prior to the major randomized clinical trial, a total of 10 participants with alcohol dependence are included in a pilot trial. This is done to examine the feasibility of the following elements:

  1. adherence to the intervention and drop-outs ii) the therapists' theoretical and practical abilities to use the virtual reality (VR) equipment iii) the time spent on virtual reality during the therapy session iv) the need for technical support v) the collaboration in the project group and vi) the participants' experience of virtual reality-assisted cognitive behavioral therapy (VRCBT).

During the pilot trial, patients receive standardized alcohol treatment for alcohol dependence at the Novavis outpatient clinics based on national guidelines from health authorities. Three of the therapy sessions contain VR-CBT.

Recruitment of participants:

Patients seeking alcohol treatment in the Novaví outpatient clinics are informed orally and in writing about the research project, and if they are interested, an information meeting is booked. If patients exhibit abstinence, these are treated prior to a possible information meeting by doctors and nurses in Novaví. If the patient wishes to participate and meets the inclusion criteria, informed consent is obtained, and screening is conducted using questionnaires described below.

Screening:

At the screening sessions, patiens medical history is obtained, as well as patients' alcohol intake over the past 30 days is recorded via Timeline Follow-back (TLFB). Patients are also asked about previous alcohol dependence treatment and general information about psychosocial factors incl. education, work, marital status, and functional level using Global Assessment of functioning (GAF). In addition, alcohol-related problems are assessed using the Alcohol Users Identification Test (AUDIT), abstinence using the Clinical Institute Withdrawal Assessment of Alcohol Scale Revised (CIWA-Ar), intake of other drugs using the Drug User Identification Test (DUDIT), alcohol craving using the Penn Alcohol Craving Scale (PACS). The Becks questionnaires, Depression Inventory 2 (BDI-II) and Beck's Anxiety Inventory (BAI), are included to assess the degree of anxiety and depression, and in addition, tests of mental function are performed using the Screening for Cognitive Impairment in Psychiatry (SCIP).

Intervention:

Included participants will in collaboration with their therapist schedule a standard course of treatment based on national guidelines from health authorities. After inclusion, participants are randomized to either:

  1. 3 sessions of VR-CBT (Group A)
  2. CBT without VR (Group B, control group)

The participants in group A are exposed to VR-simulated high-risk situations filmed in a restaurant to trigger alcohol cravings of which the participants are subsequently trained to handle by trained therapists using CBT-based techniques.

The participants in group B receive the same treatment without VR exposure. There will be weekly therapy sessions of approx. 1 hour for 3 weeks.

The intervention deviates from standard treatment, as none of the participants receive pharmaceutical alcohol treatment during the treatment period except for abstinence treatment if needed.

Randomization and blinding:

After screening the patient (ensuring that all inclusion criteria and no exclusion criteria are met) the patient is included. Participants are randomly allocated to either VR-CBT og CBT, 5 participants in each group. After randomization, the therapist ensures that the participant receives the correct treatment and performs the alcohol craving assessment during each VR-CBT session unblinded using visual analog score (VAS). The study staff conducting the remaining data collections and the entire data analysis are blinded, until the database is opened at the end of the study.

Follow-up:

Each patient must attend a follow-up visit 1 week and 1 month after the last session (session 3), where data collection will take place using the before mentioned questionnaires. The follow-up visit will be approx. 1 hour.

Statistical analysis:

All statistical analyzes are performed using the intention-to-treat principle, where all patients who have become randomized and has received a minimum of 1 session of VRCBT (group A) or CBT without VR (group B), is included in the analysis. Missing data are implemented through the multiple imputation method and the analyzes are performed in the program "R" with alpha = 0.05 and 2-sided test. All continuous effect measures are analyzed using ANOVA from baseline to most recent measurement, and categorical data are analyzed using chi2 analysis. All data distributions will be assessed for normality by visual inspection of histogram and by Q-Q plots. If data is not normally distributed, log transformation is performed, and if this is not successful, non-parametric testing is used.

Being tested
Virtual Reality Cognitive Behavioral Therapy (CRAVR), CBT
Keywords
Alcohol, Addiction, Virtual Reality, Exposure Therapy, Cognitive Behavioral Therapy
Medical subject headings
Alcoholism, Behavior, Addictive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Virtual Reality Cognitive Behavioral Therapy (CRAVR)Behavioural

    Participants in the intervention group will scheduled for 3 weekly treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations (6 different scenes from a restaurant) in virtual reality. From scene 1 to scene 6, alchol-related cues increase in intensity in order to perform gradual exposure therapy as a part of CBT. Furthermore, VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.

  • CBTBehavioural

    The active comparator receives 3 conventional cognitive behavioral therapy sessions with 1 week intervals.

Study groups in NCT04990765
Study groupRoleWhat they receive
Virtual Reality Cognitive Behavioral Therapy (VRCBT)ExperimentalThe VR exposure is performed to induce alcohol craving during the therapy session, in order to trigger a lifelike response to alcohol, while the therapist is present and able to train the participant in applying CBT-based coping strategies to deal with the alcohol cravings.
Receives: Behavioral: Virtual Reality Cognitive Behavioral Therapy (CRAVR)
Cognitive Behavioral Therapy (CBT)Active comparatorCBT is made up of the following elements: i) recognition (ii) avoiding and (iii) overcoming drinking cravings in high-risk situations with the aim of preventing relapse.
Receives: Behavioral: CBT

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Reduction in total alcohol consumption

    Percent reduction in alcohol consumption, defined as "x" grams of alcohol for past 30 days. This will be registered using the Timeline-Follow-Back (TLFB) method.

    Measured: From baseline to 1 week and 1 month after the third and final treatment session

Secondary outcomes (11)
  1. Reduction in heavy drinking days

    Based on the past 30 days of alcohol consumption using time line follow-back (TLFB), heavy drinking days are evaluated. 1 heavy drinking day consists of alcohol consumption exceeding 60/48 grams for men and women respectively.

    Measured: Baseline,1 week and 1 month follow-up

  2. Reduction in Alcohol Users Identification Test (AUDIT) score

    Screening for excessive drinking. Higher score = worse outcome

    Measured: Baseline, 1 week and 1 month follow-up

  3. Reduction in Drug User Identification Test (DUDIT) score

    Identification of individuals with drug-related problems. Higher score = worse outcome

    Measured: Baseline, 1 week and 1 month follow-up

  4. Reduction in Penn Alcohol Craving Scale (PACS) score

    Assessing alcohol craving. Higher score = worse outcome

    Measured: Baseline, 1 week and 1 month follow-up

  5. Screening for Cognitive Impairment in Psychiatry (SCIP) score

    The 20 minute test is a scale developed for screening cognitive deficits. Higher score = better outcome

    Measured: Baseline, 1 week and 1 month follow-up

  6. Reduction in Global Assessment of functioning (GAF) score

    GAF measures to what degree a person's symptoms affect their daily functioning on a scale of 0 to 100. Higher score = better outcome

    Measured: Baseline, 1 week and 1 month follow-up

  7. Becks Anxiety Inventory (BAI) score

    Measures the severity of anxiety. Higher score = worse outcome

    Measured: For baseline to 1 week and 1 month follow-up

  8. Becks Depression Inventory 2 (BDI-II) score

    Measures the severity of depression. Higher score = worse outcome

    Measured: For baseline to 1 week and 1 month follow-up

  9. Simulator Sickness Questionnaire (SSQ)

    Measures whether participants experience symptoms of simulator sickness while in Virtual Reality. Higher score = worse outcome

    Measured: Evaluated in each session

  10. VR-induced craving on a visual analog scale (VAS)

    For each of the 6 VR-scenes, craving is evaluated before, during and after exposure.

    Measured: Evaluated in each session

  11. VR-induced thoughts, emotions, physiological reactions and behavior

    Measured: Evaluated in each session

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Aug 2021
  2. Study start11 May 2021
  3. Primary completion20 Oct 2021 (estimated)
  4. Study completion20 Oct 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
single-blinded, randomized, controlled
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04990765
Sponsor's protocol ID
CRAVRPILOT
Status last verified
Jul 2021
First submitted
15 Jun 2021
Last updated
4 Aug 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Thaysen-Petersen D, Hammerum SK, Vissing AC, Oestrich IH, Nordentoft M, During SW, Fink-Jensen A. Virtual reality-assisted cognitive behavioral therapy for patients with alcohol use disorder: a randomized feasibility study. Front Psychiatry. 2024 Feb 14;15:1337898. doi: 10.3389/fpsyt.2024.1337898. eCollection 2024.

    PubMed 38419905

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Virtual Reality Cognitive Behavioral Therapy (CRAVR) and CBT in people with Alcohol Dependence, in Remission and Addiction, Alcohol, run by Psychiatric Centre Rigshospitalet at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Anders Fink-Jensen, MD, DMSc (+45 22755843, anders.fink-jensen@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Reduction in total alcohol consumption (time frame: From baseline to 1 week and 1 month after the third and final treatment session). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04990765, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2021; AzTrials last refreshed its copy on 1 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in